Therapeutic proteins are an increasingly important class of biologics and mark the technology innovation we see everyday. These proteins’ use is directly related to the treatment of rare diseases and auto-immune diseases. Other several diseases include cancer, arthritis, blood conditions or viral infections.
Medical substances such as antibodies, growth factors and cytokines can be produced and administered to patients. These substances are strong in treating and preventing diseases when muscle cells decode the therapeutic-encoding “bioblueprints”.
In this stage of activity, after the modified injection, the patient’s body starts to produce disease-fighting therapeutics. Proteins can help fight infections, control abnormal tissue growth, improve immune function, or increase the production of cellular products.
In vivo animal studies show that MYO Technology™ achieves sustained therapeutic payload production for extended periods. In some cases, lasted a year or longer, compared to conventional antibody and protein therapies, avoiding the need for frequent dosing.
New medicines are here now, not in the future. We, at RenBio, are constantly improving and changing the field of antibodies and therapeutic proteins.